by Mèo Đen » Fri Mar 30, 2018 3:58 pm
Latest info I have on this is the work by researchers from Imperial College London and the London School of Hygiene & Tropical Medicine. The promising new antibiotic, being tested is Closthioamide.
In Vitro susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae, Miari VF, Solanki P, Hieba Y, et al., 2017, In Vitro Susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae, Antimicrobial Agents and Chemotherapy, Vol:61.
Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide. This study determined the MICs of closthioamide to be 0.008 to 0.5 mg/liter for clinical N. gonorrhoeae strains and related species. Cross-resistance with existing antimicrobial resistance was not detected, indicating that closthioam-ide could be used to treat drug-resistant N. gonorrhoeae.
In conclusion, CTA has high anti-gonococcal activity in vitro, even for multidrug-resistant isolates, but further studies to evaluate the clinical potential of this antimi-crobial are urgently required in light of the public health threat that gonorrhea poses.
https://spiral.imperial.ac.uk:8443/bits ... Miari-.pdf
Latest info I have on this is the work by researchers from Imperial College London and the London School of Hygiene & Tropical Medicine. The promising new antibiotic, being tested is Closthioamide.
[b]In Vitro susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae,[/b] Miari VF, Solanki P, Hieba Y, et al., 2017, In Vitro Susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae, Antimicrobial Agents and Chemotherapy, Vol:61.
Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide. This study determined the MICs of closthioamide to be 0.008 to 0.5 mg/liter for clinical N. gonorrhoeae strains and related species. Cross-resistance with existing antimicrobial resistance was not detected, indicating that closthioam-ide could be used to treat drug-resistant N. gonorrhoeae.
In conclusion, CTA has high anti-gonococcal activity in vitro, even for multidrug-resistant isolates, but further studies to evaluate the clinical potential of this antimi-crobial are urgently required in light of the public health threat that gonorrhea poses.[url]https://spiral.imperial.ac.uk:8443/bitstream/10044/1/49402/9/Antimicrob.%20Agents%20Chemother.-2017-Miari-.pdf[/url]